Results 211 to 220 of about 208,986 (273)

Role of catecholamines in centrogenic cardiac arrhythmia induced by aconitine [PDF]

open access: bronze, 1969
Bhargava Kp   +3 more
openalex   +1 more source

Temporal profiling of M‐TEER‐related complications

open access: yesESC Heart Failure, EarlyView.
Abstract Aims Transcatheter edge‐to‐edge repair of the mitral valve (M‐TEER) is known for its low complication rates. However, the optimal level and duration of post‐procedural care remain unclear. This study aimed to identify the specific timeframe of post‐procedural complications following M‐TEER.
Jafer Haschemi   +8 more
wiley   +1 more source

SGLT2i reduce arrhythmic events in heart failure patients with cardiac implantable electronic devices

open access: yesESC Heart Failure, EarlyView.
Abstract Background Sodium glucose cotransporter 2 inhibitors (SGLT2i) represent one of the four pillars of heart failure (HF) pharmacological therapy. Objective The study aims to clarify SGLT2i antiarrhythmic effect on patients with HF with reduced ejection fraction (HFrEF) in terms of atrial and ventricular arrhythmias (AAs and VAs) reduction ...
Marco Valerio Mariani   +17 more
wiley   +1 more source

Continuous Rhythm Monitoring and Signal-Averaged Electrocardiogram to Risk Stratify Ventricular Arrhythmia in Mitral Valve Prolapse. [PDF]

open access: yesJACC Adv
Chow CL   +9 more
europepmc   +1 more source

Studies on Aconitine-induced Arrhythmias

open access: bronze, 1966
T Yanaga   +5 more
openalex   +2 more sources

Validation of a biomarker‐based mortality score for cardiogenic shock patients: Comparison with a clinical risk score

open access: yesESC Heart Failure, EarlyView.
Abstract Aims Cardiogenic shock (CS) is the deadliest manifestation of acute heart failure, with persistently high mortality rates and a lack of recent therapeutic breakthroughs. Accurate risk prediction is crucial in clinical decision‐making and the design of future clinical trials.
Elina Hynninen   +14 more
wiley   +1 more source

Burst steroid therapy and quality of life in patients with acute heart failure: Insights from the CORTAHF trial

open access: yesESC Heart Failure, EarlyView.
Abstract Aims Patients hospitalized with acute heart failure (AHF) treated with a 7 day prednisone course in the CORTAHF pilot trial had a greater improvement in health‐related quality of life (QoL) at Day 7 in both the overall population and in patients with baseline interleukin 6 > 13 pg/mL.
Matteo Pagnesi   +21 more
wiley   +1 more source

Home - About - Disclaimer - Privacy